Neuronetics’ Q2 2026 earnings reveal strong momentum: revenue jumped 9% to $41.6M, profitability is accelerating, and cash burn is shrinking. The company’s new NeuroStar sales model—offering outright purchase, leasing, or à la carte support—is driving double-digit capital sales growth even as session revenue dips. Greenbrook clinics soared 17% with smarter operations, AI-powered insurance processing, and tighter revenue cycles. Strategic moves include a partnership with ANT Neuro for neuronavigation tech and leadership changes, including a new CFO focused on profitability. The roadmap? Expand NeuroStar, optimize Greenbrook, and position for interventional psychiatry growth.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
